AIRLINK 81.10 Increased By ▲ 2.55 (3.25%)
BOP 4.82 Increased By ▲ 0.05 (1.05%)
CNERGY 4.09 Decreased By ▼ -0.07 (-1.68%)
DFML 37.98 Decreased By ▼ -1.31 (-3.33%)
DGKC 93.00 Decreased By ▼ -2.65 (-2.77%)
FCCL 23.84 Decreased By ▼ -0.32 (-1.32%)
FFBL 32.00 Decreased By ▼ -0.77 (-2.35%)
FFL 9.24 Decreased By ▼ -0.13 (-1.39%)
GGL 10.06 Decreased By ▼ -0.09 (-0.89%)
HASCOL 6.65 Increased By ▲ 0.11 (1.68%)
HBL 113.00 Increased By ▲ 3.50 (3.2%)
HUBC 145.70 Increased By ▲ 0.69 (0.48%)
HUMNL 10.54 Decreased By ▼ -0.19 (-1.77%)
KEL 4.62 Decreased By ▼ -0.11 (-2.33%)
KOSM 4.12 Decreased By ▼ -0.14 (-3.29%)
MLCF 38.25 Decreased By ▼ -1.15 (-2.92%)
OGDC 131.70 Increased By ▲ 2.45 (1.9%)
PAEL 24.89 Decreased By ▼ -0.98 (-3.79%)
PIBTL 6.25 Decreased By ▼ -0.09 (-1.42%)
PPL 120.00 Decreased By ▼ -2.70 (-2.2%)
PRL 23.90 Decreased By ▼ -0.45 (-1.85%)
PTC 12.10 Decreased By ▼ -0.89 (-6.85%)
SEARL 59.95 Decreased By ▼ -1.23 (-2.01%)
SNGP 65.50 Increased By ▲ 0.30 (0.46%)
SSGC 10.15 Increased By ▲ 0.26 (2.63%)
TELE 7.85 Decreased By ▼ -0.01 (-0.13%)
TPLP 9.87 Increased By ▲ 0.02 (0.2%)
TRG 64.45 Decreased By ▼ -0.05 (-0.08%)
UNITY 26.90 Decreased By ▼ -0.09 (-0.33%)
WTL 1.33 Increased By ▲ 0.01 (0.76%)
BR100 8,052 Increased By 75.9 (0.95%)
BR30 25,581 Decreased By -21.4 (-0.08%)
KSE100 76,707 Increased By 498.6 (0.65%)
KSE30 24,698 Increased By 260.2 (1.06%)
World

India's Bharat Biotech seeks Bangladesh trial for COVID vaccine approved at home

  • Bangladesh will from Thursday start receiving millions of India-made doses of another vaccine licensed from Oxford University and AstraZeneca.
Published January 21, 2021

DHAKA: India's Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for emergency use at home, a senior official at Bangladesh's main medical research body told Reuters.

If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use.

The vaccine, developed with the Indian Council of Medical Research, was given the green light for restricted use in India this month without any efficacy data.

"We have received their proposal. The committee will review it," Mahmood-uz-Jahan, a director at the state-run Bangladesh Medical Research Council, told Reuters, declining to give details.

The Dhaka-based International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), has applied to run the trial on behalf of Bharat Biotech, said a source with direct knowledge of the matter who declined to be named citing internal rules.

ICDDR,B declined to comment. Spokespeople for Bharat Biotech had no immediate comment.

Sinovac Biotech's late-stage trial of a potential vaccine in Bangladesh has become uncertain after Dhaka refused to meet the Chinese company's demand for co-funding.

Bharat Biotech started a late-stage trial for COVAXIN at home in November and a top Indian government vaccine official, Vinod Kumar Paul, has told Reuters that a smaller study involving 1,000-2,000 people could also be done in Bangladesh.

Bangladesh will from Thursday start receiving millions of India-made doses of another vaccine licensed from Oxford University and AstraZeneca. It is being mass produced by the Serum Institute of India, the world's largest vaccine maker.

Bangladesh, however, has no immediate plans to buy COVAXIN whose efficacy data from the late India trial are expected by March.

"Our vaccine procurement is in good shape. We are going to start the vaccination in the first week of February," Bangladesh Health Secretary Abdul Mannan told Reuters.

"No plan to buy from Bharat Biotech at present."

Brazil is the only country that has publicly announced plans to buy COVAXIN doses from India.

Comments

Comments are closed.